High-affinity transporters for norepinephrine (NE) and serotonin (5-HT), which ensure neurotransmitter clearance at the synapse, are the principal targets of widely used antidepressant drugs. Antidepressants targeting these high-affinity transporters, however, do not provide positive treatment outcomes for all patients. Other monoamine transport systems, with lower affinity, have been detected in the brain, but their role is largely unknown. Here we report that OCT2, a member of the polyspecific organic cation transporter (OCT) family, is expressed notably in the limbic system and implicated in anxiety and depressionrelated behaviors in the mouse. Genetic deletion of OCT2 in mice produced a significant reduction in brain tissue concentrations of NE and 5-HT and in ex vivo uptake of both these neurotransmitters in the presence of the dual 5-HT-NE transport blocker, venlafaxine. In vivo clearance of NE and 5-HT evaluated using microiontophoretic electrophysiology was diminished in the hippocampus of OCT2 À/À mice in the presence of venlafaxine, thereby affecting postsynaptic neuronal activity. OCT2 À/À mice displayed an altered sensitivity to acute treatments with NE-and/or 5-HT-selective transport blockers in the forced-swim test. Moreover, the mutant mice were insensitive to long-term venlafaxine treatment in a more realistic, corticosterone-induced, chronic depression model. Our findings identify OCT2 as an important postsynaptic determinant of aminergic tonus and mood-related behaviors and a potential pharmacological target for mood disorders therapy.
Introduction
Neurotransmitter transporters exert a crucial role in the control of synaptic transmission by ensuring the rapid clearance of the released transmitters from the synaptic cleft and their recycling into the nerve endings. In monoaminergic pathways, this clearance is carried out principally by high-affinity sodiumdriven transporters for dopamine (DA), 5-HT and norepinephrine (NE), embedded in the plasma membrane of the presynaptic terminal. These high-affinity reuptake transporters are the primary target for various psychoactive compounds including some of the classical antidepressants, which potently inhibit the serotonin (SERT) and/or norepinephrine (NET) transporters. 1, 2 This notion has been for decades a compelling argument in support of the 'monoamine' hypothesis of depression, which assumes that hypoactivity of 5-HT and NE pathways occurs during depression that can be counterbalanced by antidepressant treatment. 3 Central serotonergic and noradrenergic pathways control a wide range of functions including mood and emotion, and dysfunction of these circuits has indeed been implicated in the etiology and physiopathology of anxiety and depression. 4 Although the critical role of the high-affinity transporters in monoamine clearance and antidepressant action is firmly established, it has been suspected for years that additional monoamine clearance systems may exist in the brain. Low-affinity monoamine uptake through non-cognate transporters has been suggested in earlier studies using transport, voltammetry or microdialysis approaches, and selective blockers and mouse mutants for the high-affinity transporters. [5] [6] [7] The rigorous interpretation of these studies has been confounded, however, by the limited knowledge concerning the specificity of the inhibitors used as pharmacological tools. Thus, the physiological function of these low-affinity uptake components in central nervous system has remained elusive. Potential candidates that could ensure low-affinity monoamine transport in the brain include the organic cation transporter (OCT) family [8] [9] [10] and the plasma membrane monoamine transporter (PMAT), 11 all of which have the capacity to transport aminergic neurotransmitters in vitro. OCTs have been investigated principally for their role in the handling of organic cations in peripheral organs, 12, 13 and are currently emerging as novel but ill-characterized components of aminergic neurotransmission. Mice deficient for OCT3 show changes in the neural and behavioral responses to environmentally induced variations in osmolarity, altered monoamine neurotransmission in the brain and increased sensitivity to psychostimulants, 9, 14 suggesting a 'back-up' role in monoamine clearance, supported by studies of mice lacking SERT. 15 OCT3 was also shown to have an important role in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in dopaminergic pathways, by allowing the release of the neurotoxic derivative MPP þ in the extracellular space. 16 OCT2 is another member of the OCT family, which was detected previously in the brain. 10, 17 On the basis of its ability to transport 5-HT and NE, we hypothesized that this transporter could modulate monoaminergic neurotransmission in complement to the high-affinity transporters, and have a role in the control of mood and related functions. To test this possibility, we investigated the contribution of OCT2 to monoamine clearance in vivo in the brain and its functional consequences on postsynaptic neuronal activity, as well as on anxiety and depression-related behaviors and the response to antidepressants.
Materials and methods

Animals
OCT2
À/À mice were previously generated by homologous recombination. 13 Heterozygous animals with 10 backcross generations into C57BL6/J were bred to generate wild-type and knockout littermates, which were genotyped as described previously 13 and 8-12 weeks-old mice were used for the experiments. Animal care and experiments were conducted in accordance with the standard ethical guidelines (European Communities Council Directive for the Care and Use of Laboratory Animals, 86/609/EEC) and approved by local ethical committees.
Immunohistochemistry and immunoautoradiography
Free-floating immunohistochemistry was performed as detailed in Supplementary Material and Methods. For immunoautoradiography, kidney or brain cryosections were fixed with 4% paraformaldehyde/PBS and incubated successively with OCT2 (1/500), OCT3 (1/500) 9 or PMAT antibodies raised against peptide sequence YLHHKYPGTSIVF (1/500; Agro-Bio, La Ferté St Aubin, France), and with [ 125 I] anti-rabbit IgGs (Perkin Elmer, Boston, MA, USA) and exposed to film for 3-8 days. Analysis and quantification of autoradiograms were carried out with MCID software (Imaging Research, Brock University, St Catherines, Ontario, Canada).
Monoamine uptake
Mice were killed by decapitation and the hippocampus and frontal cortex were dissected, minced on ice and resuspended in ice-cold sucrose (0.32 M). The cells were dissociated by filtering through nylon meshes of decreasing pore size (180-60 mm, Small Parts, Miramar, FL, USA) and resuspended in ice-cold sucrose. 3 H] glutamate (Perkin Elmer). The effect of citalopram on endogenous OCT2 activity was evaluated in the presence of increasing concentrations of this antidepressant (0.1-10 mM) during preincubation and uptake. The reaction was terminated by rapid filtration through Unifilter-96 GF/C filters (Perkin Elmer), and after washing the radioactivity retained on the filters was assessed by liquid scintillation. The protein concentration in tissue extracts was measured by Bradford's method. OCTmediated uptake was quantified by inhibition with the specific inhibitor decynium 22 (D22) (1,1 0 -diethyl-2,2 0 -cyanine iodide) 18 (500 mM; Sigma-Aldrich). Data are expressed as mean±s.e.m. of D22-sensitive uptake for 4-6 independent experiments performed in triplicate.
Determination of monoamine brain content Brain structures were assessed for monoamine and metabolite content by high-performance liquid chromatography as previously reported. 19 Iontophoretic electrophysiology Extracellular recordings of pyramidal neurons in the CA3 region of the hippocampus were carried out using multi-barreled glass micropipettes as described in Supplementary Material and Methods. 20 In agreement with its ability to block both NE and 5-HT reuptake in mice, 21 venlafaxine at the dose of 16 mg per kg, subcutaneous, but not 8 mg per kg, produced a reduction of the firing rate of CA3 pyramidal neurons in wild-type and OCT2
À/À mice. The excitatory current of quisqualate was thus increased for both groups to maintain a firing activity rate similar to that before venlafaxine injection at the dose of 8 mg per kg. The time required for the firing activity to recover 50% of the initial firing rate after microiontophoretic application (recovery time (RT 50 ) value) was used as an index of the capacity of neurons of the dorsal hippocampus to remove NE or 5-HT from the synaptic cleft in the presence or absence of venlafaxine (8 and 16 mg per kg). 21 Receptor and transporter autoradiography Male mice were killed by cervical dislocation and brains were rapidly extracted and frozen on dry ice. Behavioral and pharmacological studies Most behavioral studies were performed during the inactive phase (09:00-13:00) with age-matched (8-10 weeks), naive mice. Each group was composed of balanced numbers of both genders and similar effects of genotype were observed for male and female mice.
General locomotor activity was assessed in activity chambers (25 Â 15 Â 20 cm) placed in a rack containing four infrared photobeams located 15 mm above the floor along the long axis. Photobeam interruptions were recorded during 2 h with a six-channel amplifier connected to a computer (Imetronic, Bordeaux, France). Motor coordination was evaluated with a rotating rod apparatus (Bioseb, Chaville, France) with speed increased linearly from 4 to 40 r.p.m. during a 5-min observation period. Mice were given five trials separated by 30 min intervals and scored for their latency to fall off the rotarod.
The open field consisted of a white Plexiglas field (100 Â 100 Â 30 cm) with the center brightly illuminated (500 lux). General locomotor activity in the center and periphery of the open field were scored for 9 min. The time and number of entries in the center zone (60 Â 60 cm) were evaluated as an index of anxiety-related response.
The elevated O-maze consisted of an annular runway positioned 40 cm above the floor and divided into two opposing 901 closed sectors and two 901 open sectors. The mice were individually placed in the closed sector and their behavior recorded over a 5-min period. The time spent in each sector and the number of sector entries (a sector entry was defined as all four of the paws being placed in a sector) were determined by video tracking (Viewpoint, Lyon, France).
Novelty-suppressed feeding was performed as previously described. 25 The mice were food-restricted for 24 h with water ad libitum, and the test performed in a brightly lit (800-900 lux) square arena (40 Â 40 Â 20 cm) with a standard food pellet (6 g) at the center. The latency to feed was assessed and the animals immediately transferred to their home cage, where food consumption was measured for 10 min. The animals were weighed before and after food deprivation. Food consumption in the home cage and percentage of weight lost after food deprivation were used as relative controls for animal hunger. Immobility was evaluated in the forced swimming and the tail suspension tests. In the forced-swim test, the mice were placed individually in a glass beaker filled with 25±1 1C water to a depth of 12 cm. 26 The duration of immobility (that is, the time during which the mice make only minimal movements to stay afloat) was recorded during the last 4 min of the 6-min testing period, after 2 min of habituation. In the tail suspension test, mice were suspended in the test apparatus and immobility time was automatically recorded during a 6-min test session (Bio-TS, Bioseb). Venlafaxine (Tocris Bioscience), reboxetine (Pfizer, Groton, CT, USA) and citalopram (Lunbeck, Copenhagen, Denmark) were dissolved in saline (0.9% NaCl [wt/vol]) and administered intraperitoneally in a volume of 10 ml per kg 30 min before forced swim.
For the sucrose preference test, singled-house mice were first habituated for 48 h to drink water from two bottles. On the following 3 days, the mice could choose between a water bottle and a 1% (wt/vol) sucrose solution bottle, switched daily. Sucrose solution intake for 24 h was measured during the last 2 days and expressed as a percentage of the total amount of liquid ingested.
The splash test was carried out in home cage and consisted in spraying 200 ml of a 10% (wt/vol) sucrose solution on the mouse's snout using a small atomizer. The grooming frequency and latency were then recorded for 5 min.
The coat state was evaluated as the sum of the score of different parts of the body, ranging between 0 for a well-groomed coat and 2 for an unkempt coat for head, neck, dorsal/ventral coat, and between 0 and 1 for tail and forepaws/hindpaws.
The social interaction test was performed in a white plastic arena (42 Â 42 cm) containing an empty wire mesh cage (10 Â 6.5 cm) at an extremity of the field and monitored by video tracking (Viewpoint). The test male mouse was allowed to explore the arena for two consecutive 2.5-min sessions. During the second session, an unfamiliar male mouse that had no previous contact with the subject mice was placed in the cage. The time spent by the test mouse in the interaction zone, that is, an 8-cm-wide region surrounding the mesh cage and the opposite corners of the arena was measured in both sessions.
To induce a chronic depression-like state, individually housed male mice were administered corticosterone (35 mg ml
À1
; Sigma-Aldrich) dissolved in 0.45% (wt/vol) hydroxypropyl-b-cyclodextrin (Sigma-Aldrich) or vehicle (0.45% hydroxypropyl-b-cyclodextrin) in drinking water during 7 weeks. 27 After 4 weeks, the mice were tested during the light phase successively for coat state, sucrose consumption, social interaction, elevated O-maze, splash test and novelty-suppressed feeding. Venlafaxine was administered daily (16 mg per kg per day, intraperitoneally, between 17:00-19:00) during the last 3 weeks of the corticosterone regimen and the mice tested again. Plasma corticosterone concentrations were determined using radioimmune assay kits (MP Biomedicals, Solon, OH, USA) and expressed as ng ml -1 of plasma. 
Statistics
Results
OCT2 is enriched in the limbic system
The anatomical distribution of OCT2 was investigated by immunohistochemistry on mouse brain sections with affinity-purified antibodies raised against a synthetic peptide corresponding to an epitope of the rodent protein diverging from other OCT subtypes. Expression of OCT2 was widespread, but notably enriched in specific areas. Specifically, strong OCT2 labeling was found in the frontal cortex, shown here for primary and secondary motor and cingulate cortices ( Figure 1a ), in CA2, CA3 and CA1 of the hippocampus ( Figure 1b ) and in the amygdala ( Figure 1c ). In contrast, OCT2 was only detected in some aminergic neuron-containing regions, such as the locus coeruleus ( Figure 1d ) and dorsal raphe ( Figure 1e ) but not in the substantia nigra or ventral tegmental area (not shown). In the locus coeruleus, OCT2 was found in most but not all noradrenergic neurons, labeled by tyrosine hydroxylase antibodies ( Figure 1d ). In the dorsal raphe, OCT2 was weakly expressed in a fraction of serotonergic neurons, labeled by tryptophan hydroxylase antibodies ( Altogether, these experiments indicate that OCT2 is markedly expressed in the limbic regions of mouse brain.
OCT2 controls anxiety-related behavior and immobility in the forced-swim and tail suspension tests The limbic and prefrontal cortical regions, which express the highest levels of OCT2, have an important role in the response to stress or threats 28 and in mood disorders. 4, 29, 30 We thus carried out a set of moodrelated behavioral tests to assess the level of anxiety (open-field, elevated O-maze and novelty-suppressed feeding) and so-called behavioral despair (forcedswim and tail suspension tests) of OCT2 À/À mice. OCT2
À/À mice characterized previously are normally viable and fertile, and standard histological analysis did not show evident morphological anomalies. 13 General locomotor activity of the mutants evaluated in an actimeter chamber was similar to that of wild types, while motor coordination in a rotarod test was slightly impaired (Supplementary Figure 2) . In the open-field apparatus, which evaluates locomotor activity in a novel environment as well as the level of anxiety, activity at the periphery of the open field was comparable for the two genotypes (Figure 2a . In a third paradigm, novelty-suppressed feeding, which evaluates the latency of the animal to consume food in a novel aversive environment, OCT2 À/À mice exhibited a decreased latency to feed in comparison with wild-type mice, whereas body weight loss and food consumption in the home cage were similar in both groups ( Figure 2c ). These experiments show that OCT2 deficiency in mice results in decreased anxiety level, as evaluated by these three conflict paradigms. Next, we assessed immobility during exposure to inescapable stress using the forced-swim and the tail suspension tests, two tests classically used to evaluate the efficacy of antidepressants. In these two paradigms, OCT2 À/À mice showed a marked increase in immobility time compared with wild-type mice, indicative of an increased level of resignation (Figure 2d and e). Thus, consistent with its predominant expression in limbic regions, OCT2 is implicated in the control of moodrelated behaviors like anxiety and acute 'behavioral despair' in antidepressant-related tests.
OCT2 participates in 5-HT and NE clearance in aminergic projection regions Based on OCT2 properties established in vitro, 31 we speculated that this transporter could participate in monoamine uptake in the limbic system, broadly innervated by monoaminergic fibers. To examine the transport properties of endogenous OCT2, we measured monoamine uptake ex vivo in fresh cell suspensions from two regions with high OCT2 expression, hippocampus and cortex, from wild-type and OCT2
À/À mice (Figure 3a) . Uptake of tritiated NE, 5-HT and DA was carried out in the presence of highaffinity monoamine transporter inhibitors and sodium-depleted buffer, in order to minimize transport by high-affinity systems. The contribution of OCT-mediated uptake to total uptake, evaluated with the selective OCT inhibitor D22, 18 was compared between wild-type and mutant mice. These experiments showed D22-sensitive uptake of the three monoamines in extracts from wild-type mice hippocampus ( Comparison of D22-sensitive uptake in extracts from the two genotypes showed a significant decrease in transport activity in OCT2 À/À mice compared with wild types for NE and 5-HT in both hippocampus and cortex, whereas DA uptake was not significantly different between genotypes (Figure 3a) , nor that of another neurotransmitter not transported by OCT2, glutamate (not shown).
Tissular levels of NE, 5-HT and DA were evaluated by high-performance liquid chromatography in wildtype and OCT2
À/À mice. OCT2 deletion was associated with significant reductions in the content in NE and 5-HT in several brain regions (Figure 3b ). The most conspicuous difference between genotypes was a decrease in intra-tissular level of NE in the cortex and hypothalamus (38% and 22%, respectively); significant differences were also found in the striatum, hippocampus, brain stem and cerebellum (Figure 3b) . Similarly, a decrease in the intra-tissular level of 5-HT was detected in the striatum (20%), hippocampus (19%) and hypothalamus (27%) ( Figure  3b ). No significant differences were found for endogenous DA levels (not shown), in agreement with the results of ex vivo DA uptake.
The above experiments suggest that OCT2 participates in NE and 5-HT clearance in aminergic projection regions of the brain. To explore the functional consequences of OCT2 deletion on 5-HT and NE clearance, the activity of postsynaptic neurons was investigated in vivo by a combined microiontophoretic and electrophysiological approach in the hippocampus CA3, one of the regions with the highest OCT2 density. As previously reported, 32 microiontophoretic applications of 5-HT and NE resulted in the suppression of the firing activity of CA3 pyramidal neurons. In both wild-type and OCT2
À/À mice, this firing gradually recovered upon the cessation of the application of monoamines (Figure 3c, top) . The recovery time for pyramidal neuron firing, before and after acute systemic administration of venlafaxine (8 or 16 mg per kg), was expressed as RT 50 values (Figure 3c, bottom) . In basal conditions, RT 50 values for NE or 5-HT did not differ between wild-type and OCT2 À/À mice (Figure 3c , bottom). These RT 50 values were significantly increased in both wild-type and OCT2
À/À mice after the administration of the dual 5-HT-NE transport inhibitor venlafaxine at 16 mg per kg ( Figure 3c ). However, in contrast to basal conditions, RT 50 values after venlafaxine administration at doses of both 8 and 16 mg per kg were significantly higher in OCT2 À/À than in wild-type mice (Figure 3c ). These observations indicate that OCT2 can promote the recovery of the firing activity of CA3 hippocampal neurons after NE and 5-HT application in vivo, in particular when the NET and SERT are pharmacologically inactivated. Thus, OCT2 appears to have a key role in the modulation of postsynaptic neuronal activity in response to the antidepressant venlafaxine.
To rule out the fact that the differences in uptake and clearance detected in OCT2 À/À mice could be due to adaptative changes in the expression of other highor low-affinity transporters in the brain, the levels of NET, SERT, OCT3 and PMAT were quantified on brain sections of mutants and wild-type mice by binding of specific radiolabeled ligands or immunoautoradiography. These experiments showed that in most brain regions these transporters were expressed at a comparable level in OCT2
À/À and wild-type mice (Figure 3d and Supplementary Tables 1 and 2 ). NET and PMAT levels were similar in most brain regions (Figure 3d and Supplementary Table 1) . A moderate increase in SERT density was found in the hippocampus (8% and 14%, respectively for CA3 and dentate gyrus) and cingulate cortex (25%), while OCT3 level was increased of 25% in the hippocampus CA3 (Figure 3d and Supplementary Table 2 ). No decrease in the level of these transporters was detected, confirming that the differences in D22-sensitive NE and 5-HT uptake and in vivo clearance between wild-type and OCT2 À/À mice reflected indeed lack of OCT2 activity.
Finally, to better identify the pre-and/or postsynaptic sites of OCT2-mediated uptake, we explored by immunohistochemistry the fine subcellular localization of OCT2 in aminergic projection regions. In all neurons, OCT2-specific labeling was circumscribed to the soma and plasma membrane in the cell body and dendrites, as shown by microtubule-associated protein 2 co-labeling in the cortex, hippocampus and amygdala (Figure 3e ). OCT2 was not detected in presynaptic nerve endings labeled with antibodies against the synaptic vesicle protein synaptophysin, shown here in the cingulate cortex and hippocampus CA3 (Figure 3f ). OCT2 appears thus strategically located for NE and 5-HT clearance at the plasma membrane of the dendrites and body of neurons in projection areas. Collectively, this set of experiments strongly suggests that OCT2 controls 5-HT and NE À/À mice brain is expressed as mean±s.e.m. of percentage values of wild type. Student's t-test, paired, two-tailed, NE: HPC, t 5 = 3.1, *P = 0.028; Cx, t 5 = 7.2, ***P = 0.0008; 5-HT: HPC, t 5 = 11.6, ***P < 0.0001; Cx, t 5 = 4.96, **P = 0.0042; n = 6. (b) Decreased intra-tissular level of NE and 5-HT in OCT2 À/À mice brain. High-performance liquid chromatography (HPLC) results are presented as mean±s.e.m. Student's t-test, unpaired, two-tailed, NE: cortex, t 9 = 2.5, *P = 0.0338, n = 5-6; striatum, t 10 = 2.6, *P = 0.025, n = 6; hippocampus, t 10 = 3.1, *P = 0.012, n = 6; brain stem, t 9 = 3.5, **P = 0.007, n = 5-6; cerebellum, t 10 = 2.5, *P = 0.03, n = 6; 5-HT: striatum, t 10 = 2.8, *P = 0.019, n = 6; hippocampus, t 10 = 2.4, *P = 0.037, n = 6; hypothalamus, t 9 = 3.6, **P = 0.0055, n = 5-6. 
-HT). (d) Diminished clearance in OCT2
À/À mice cortex and hippocampus is not due to alterations in the expression of other high-or low-affinity transporters. All transporters are found at a comparable or increased level in mutant mice. IL, infralimbic cortex; Cg, cingulate cortex; DG, dentate gyrus. Student's t-test, unpaired, two-tailed, SERT: Cg, t 9 = 2.6, *P = 0.026; CA3, t 9 = 4.1, **P = 0.0028; DG, t 9 = 2.6, *P = 0.028; OCT3: CA3, t 9 = 2.5, *P = 0.034 ; n = 5-6. Representative sections of specific ligands binding (NET and SERT) or immunoautoradiography (OCT3 and plasma membrane monoamine transporter (PMAT)) are shown on the right. Values are given as mean±s.e.m. (e-f) Expression of OCT2 in the body and dendrites of aminergic projection neurons. Immunofluorescent histochemistry of coronal brain sections. OCT2 is distributed in the somato-dendritic compartment, shown by double labeling with microtubule-associated protein 2 (MAP2) antibodies in neurons of layer V of the motor cortex (Cx), hippocampus CA1 and basolateral amygdala nucleus (BLA) (e). OCT2 does not colocalize with the presynaptic side of nerve endings labeled with antibodies against the synaptic vesicle protein synaptophysin, shown in cortex and hippocampus CA3 (f). Scale bars represent 20 mm (e) and 10 mm (f).
clearance at the postsynaptic level in limbic regions of the brain, and can modulate neuronal activity in these regions in vivo in presence of the antidepressant venlafaxine.
OCT2 modulates the sensitivity to antidepressants in the forced-swim test To determine whether OCT2 is implicated in the action of antidepressants, the behavioral response to these drugs were investigated in OCT2 À/À mice using the forced-swim paradigm. In comparison with wildtype mice, OCT2
À/À mice showed altered sensitivity to three antidepressants: the dual 5-HT/NE reuptake inhibitor venlafaxine and the NET-and SERT-selective reuptake inhibitors, reboxetine and citalopram, respectively (Figures 4a-c) . When treated with low doses of antidepressants, otherwise inactive in wildtype animals, OCT2
À/À mice showed a marked sensitivity to the immobility-reducing effects of all three compounds (Figures 4a-c) . At increasing doses of venlafaxine, the mutants showed a progressive reduction of immobility time similar to that found in wild-type animals (Figure 4a) . A similar progressive reduction of immobility time was also induced by increasing doses of reboxetine, but at the dose of 20 mg per kg this reduction was markedly stronger in the mutants than in wild-type animals, demonstrating increased sensitivity (Figure 4b ). In contrast, medium to high doses of citalopram did not elicit a further reduction in immobility in the mutants as in normal mice, indicating decreased sensitivity at these higher doses (Figure 4c ). To investigate whether this decreased sensitivity could be a consequence of a direct interaction of citalopram with OCT2, [ (Figure 4d) . These experiments showed that citalopram had no significant action upon OCT2-mediated uptake ex vivo. Thus, to further characterize the modifications in the serotonergic systems that could underlie the pharmacological phenotype of OCT2 À/À mice, the levels of 5-HT1A receptors were evaluated by [ 3 H] WAY100635 binding on sections of mutants and wildtype mice brain. 5-HT1A receptor density throughout the brain showed a low but significant decrease in the cingulate cortex (14%), lateral septal nucleus (14%) and CA1 of hippocampus (8%) of mutant mice (Supplementary Table 3 ), confirming that subtle alterations occur in serotonergic neurotransmission pathways. Taken together, these results reveal that OCT2 is an important modulator of the response to NE-and 5-HT-selective antidepressants in the forcedswim test.
OCT2 is required for the response to long-term venlafaxine treatment in a corticosterone-induced depression model Long-term administration of corticosterone can induce in rodents a panel of behavioral anomalies that mimic diverse aspects of human depression and can be improved by long-term antidepressant treatment. 27, 33 To investigate the pathophysiological relevance of our findings to human depression, we examined whether OCT2 À/À mice showed alterations in the response to long-term venlafaxine treatment using this chronic corticosterone paradigm, which also presents the advantage of leveling out and overriding uncontrollable variations in corticosterone secretion over time (Figure 5a ). Mutant and wild-type mice were evaluated in basal conditions and following chronic corticosterone administration with a battery of tests known to recapitulate diverse anomalies observed in depression. Sucrose solution consumption was used to monitor the progression of anhedonia. The elevated O-maze and the novelty-suppressed feeding test are conflict paradigms reflecting anxiety level, whereas grooming behavior in the splash test and coat state are indicators of the state of behavioral despair of the animals. After a 4-week corticosterone exposure (5 mg per kg per day), OCT2
À/À and wildtype mice showed enhanced and comparable levels of circulating corticosterone (117 ± 13 ng ml À1 and 111±17 ng ml
À1
, respectively) and robust alterations indicative of a depressed-like state in sucrose consumption, elevated O-maze, splash test performance and coat state (Figure 5b) , as well as in social interaction and novelty-suppressed feeding (Supplementary Figure 3 ). To determine the sensitivity to chronic administration of antidepressants, corticosterone-treated OCT2
À/À and wild-type mice were again tested after a 21-day treatment with 16 mg per kg per day venlafaxine. Long-term venlafaxine reversed the effects of chronic corticosterone in wildtype mice in sucrose consumption, elevated O-maze, splash test performance and coat state, but failed to improve the performances of OCT2 À/À mice ( Figure 5c ). No effect of venlafaxine was observed on both genotypes in the other two tests, social interaction and novelty-suppressed feeding (not shown). Indeed, although OCT2 À/À mice were as sensitive as wild-type mice to the effects of chronic corticosterone exposure on the development of an overall depressed-like phenotype, they failed to develop, in contrast to wild-type mice, an improvement of this depressed phenotype upon long-term venlafaxine treatment. OCT2 appears thus to be required for the full long-term effects of venlafaxine in a chronic corticosterone-induced depression model.
Discussion
Until recently, the high-affinity reuptake transporters were considered the principal elements responsible for the clearance of monoamines at nerve endings. The body of neurochemical and electrophysiological evidence presented herein demonstrates that a lowaffinity, high-capacity transporter, OCT2, is an important actor in NE and 5-HT clearance in vivo in the limbic brain. Ex vivo transport experiments and in vivo combined microiontophoresis and electrophysiology indicated that OCT2-mediated clearance, although subtle, is an intrinsic component of the recovery of 5-HT and NE-suppressed firing activity of postsynaptic neurons in a monoaminergic projection region, the hippocampus CA3, once the high-affinity transporters are inhibited. Such a low-affinity 5-HT clearance component was previously detected by high-speed chronoamperometry in the hippocampus of rats after SERT blockade 7 and of SERT mutant mice, and shown to be sensitive to the OCT inhibitor D22. 15 Clearance via OCT2 could have important consequences on NE and/or 5-HT signaling in conditions of monoamine spillover in the presence of antidepressants but also in areas of lesser high-affinity transporter density, at distance from the aminergic varicosities. Consistently, OCT2 was found in strategic postsynaptic locations to ensure this dual function, that is, at the plasma membrane and in the somato-dendritic compartments of neurons in regions of aminergic projections in the brain. Paracrine, or 'volume' transmission, is a well-established mode of transmission for monoamines, which varies depending on brain region. Diffusion of monoamines to sites remote from the nerve end terminals has been demonstrated by cyclic voltammetry for 5-HT in the dorsal raphe and substantia nigra reticulata, 34 for catecholamines in mouse prefrontal cortex 35 and for NE in the upper layers of cingulate and sensory cortices, where it may travel up to 100 mm 36 and thus be amenable to uptake by OCT2. The participation of OCT2 in physiological NE and 5-HT uptake in basal conditions is sustained by the decreased intra-tissular concentrations of these neurotransmitters in aminergic projection regions in OCT2 À/À mice in the absence of any pharmacological treatment. Although less pronounced, this observation is reminiscent of the reduction in monoamine content found in the brain of SERT-and NET-deficient mice. 37, 38 Limbic and prefrontal cortical regions are known to modulate the autonomic and endocrine responses to stress or threats 28 and mediate cognitive and emotional aspects of mood disorders. 4, 29, 30 Specific anatomical 30, 39 and functional 30, 40, 41 anomalies of these systems have been detected in patients with major depression or bipolar disorder. Alterations of anxiety and immobility in the tail suspension test and forced-swim test in OCT2 À/À mice could thus be the consequence of impaired 5-HT and NE clearance in these limbic regions, all extensively innervated by serotonergic and noradrenergic fibers, although the precise mechanisms implicated are still to be determined. In addition to these areas, regions expressing lower levels of OCT2, such as the locus coeruleus and the dorsal raphe, also implicated in mood-related behavior and the response to antidepressants, 42 could have a part in the overall phenotype of the mutants. Although less likely, it cannot be totally excluded that other structures weakly expressing OCT2, such as microvessels, 43 might be implicated as well. Following acute stress, including inescapable stress like forced swim, specific serotonergic and noradrenergic pathways are activated within minutes to trigger the activation of the hypothalamic-pituitary-adrenocortical axis, through direct and indirect connections to the paraventricular nucleus and peri-paraventricular nucleus regions. [44] [45] [46] [47] OCT2 deletion could thus potentiate the effect of 5-HT and NE release during this activation in raphe and projection areas like hippocampus, amygdala and prefrontal cortex. [48] [49] [50] Furthermore, selective activation of postsynaptic 5-HT1A receptors has been shown to attenuate behavioral despair 51, 52 and promote anxiety, 53 suggesting that the decrease in 5HT1A receptor density in projection regions in OCT2 À/À mice could contribute to accentuate their overall phenotype. Similar adaptive modifications in the expression or activity of 5-HT1A receptors have been observed after long-term increase in extracellular 5-HT 54 and SERT deficiency. 19, 55 Our study disclosed that OCT2 is a critical element for the behavioral response to antidepressants in both acute and long-term paradigms. In the forced-swim test, the genetic inactivation of OCT2 potentiated the antidepressant-like effects of pharmacological blockade of the high-affinity transporters by selective serotonin (SSRIs), norepinephrine (NRIs) and dualselective (SNRIs) reuptake inhibitors. These reuptake inhibitors are believed to exert their actions mainly by elevating synaptic and/or extrasynaptic 5-HT and NE, 21 a concept that has been decisive to implicate serotonergic and noradrenergic mechanisms in the physiopathology of depressive disorders. The hypersensitivity of OCT2 À/À mice to NE and 5-HT uptake inhibitors at doses inactive in wild-type animals fits well with a simple scheme where the clearance of À/À mice, provoking anhedonia, increasing anxiety and inducing deterioration of grooming behavior and coat state. Two-way analysis of variance (ANOVA) (n = 10-14) reveals a significant effect of corticosterone treatment on sucrose consumption (F 1,37 = 53.9; P < 0.0001), time in open zone in elevated O-maze (F 1,42 = 18.1; P < 0.0001), grooming frequency in splash test (F 1,41 = 37.8; P < 0.0001) and coat state (F 1,50 = 301.1; P < 0.0001). Fisher's post-hoc test, *P < 0.05, **P < 0.01, ***P < 0.001 versus untreated mice. Decreased anxiety and increased grooming behavior at basal state are found in OCT2 À/À mice, # P = 0.019 and # P = 0.044 versus wild-type mice, respectively. (c) OCT2 À/À mice are insensitive to reversal of corticosterone-induced depression-like behaviors by long-term venlafaxine treatment. Two-way ANOVA (n = 6-12) reveals a significant effect of venlafaxine on sucrose consumption (F 1,39 = 5; P = 0.032), grooming frequency in splash test (F 1,37 = 5.7; P = 0.022) and coat state (F 1,22 = 4.6; P = 0.043). Fisher's post-hoc test reveals significant effect of venlafaxine in wild-type mice for sucrose consumption (***P = 0.0004), splash test (*P = 0.047) and coat state (**P = 0.0046), but not in OCT2 À/À mice (P = 0.54, 0.21 and 0.82 for sucrose consumption, splash test and coat state, respectively). Confirming this effect, significant differences are found between venlafaxine-treated wild-type and OCT2 À/À mice in sucrose solution intake ( ## P = 0.0011) and coat state ( ## P = 0.0068). Unpaired two-tailed Student's t-test revealed significant effects of venlafaxine in elevated O-maze (t 10 = 2.7, y P = 0.021, n = 6) in wild-type and not in OCT2 À/À mice (t 11 = 0.2, P = 0.83, n = 6-7). All values are given as mean±s.e.m. both 5-HT and NE neurotransmitters is diminished in the mutants due to the absence of OCT2, thereby intensifying the increase in synaptic NE and 5-HT concentrations provoked by the antidepressants. As we showed here, this effect was not due to decreased NET or PMAT expression, which was found unaltered, nor SERT or OCT3 expression, which appeared rather increased in the mutants. In addition, OCT2 À/À mice showed a relative insensitivity to higher doses of citalopram. As several antidepressants including citalopram have been shown to inhibit OCTs in heterologous systems, 56 we investigated whether this decreased sensitivity could be a consequence of a direct inhibition of OCT2 by this antidepressant. Citalopram had no significant action upon D22-sensitive OCT2-specific uptake ex vivo, arguing against a major inhibitory effect on transport through direct interaction with OCT2. Acutely, 5-HT and dualselective reuptake inhibitors provoke the inhibition of serotonergic neurons firing through the local activation of the 5-HT1A autoreceptors of the raphe. This mechanism, believed to dampen their effect on 5-HT extracellular levels in projection areas, 57 is enhanced at high concentrations of citalopram. 58 At high doses of citalopram, impaired 5-HT clearance in raphe of OCT2 À/À mice could thus displace this equilibrium in favor of feedback inhibition. Alternatively, decreased activity at postsynaptic 5-HT1A receptors, shown to mediate the anti-immobility effects of antidepressants in the forced-swim paradigm, 52, 59 could also participate in this effect.
Acute 'behavioral despair' tests such as the forcedswim test, although useful to evaluate antidepressant efficacy, fall short of recapitulating the complex spectrum of cognitive and emotional dysfunctions found in depressive disorders. Chronic stress and more recently chronic corticosterone exposure have been used to develop more realistic models in rodents, encompassing distinct facets of depression such as anhedonia, anxiety, social aversion and resignation. 33, 60 Importantly, the persistent behavioral anomalies induced in these models can be improved by long-term, but not acute, antidepressant treatment, 33 ,60 a characteristic shared with human depression. Thus, to gain more insight into the role of OCT2 in depression and antidepressant response, we induced a general depression-like phenotype by chronic corticosterone exposure. OCT2 À/À mice developed as efficiently as wild-type mice a depressed-like phenotype after chronic corticosterone exposure. In wild-type mice, long-term venlafaxine treatment reversed the depression-like anomalies induced by chronic corticosterone, an effect that had been previously reported for fluoxetine and imipramine. 33, 60 In contrast, the overall depressed-like phenotype of OCT2 À/À mice after corticosterone exposure was insensitive to venlafaxine treatment, indicating that OCT2 is required for the full long-term effect of this antidepressant. This observation, radically contrasting with the hypersensitivity observed in the forced-swim test, can be explained by the fact that antidepressants take several weeks to exert their therapeutic actions in man as well as in animal models, and trigger mechanisms that differ, at least in part, from those implicated in their short-term action. The complex alterations that underlie their emotional and behavioral effects occurring over time require both neurogenesis-dependent and -independent processes, 27, 61, 62 such as the progressive desensitization of 5-HT1A autoreceptors. 63 As venlafaxine inhibits both NE and 5-HT reuptake, we can speculate that OCT2 deficiency impairs noradrenergic and/or serotonergic signaling in yet undetermined circuits that promote the long-term effects of this antidepressant. Long-term treatment with NRIs and SNRIs, including venlafaxine, is known to progressively attenuate the firing of NE neurons of the locus coeruleus, possibly via modulation of a2-adrenoceptor function. 62, [64] [65] [66] Enhanced NE concentrations in the locus coeruleus or projection regions due to OCT2 deficiency might thus be expected to antagonize the long-term action of venlafaxine. In addition, other mechanisms, such as the constitutive increase in SERT level or decreased activity of 5-HT1A receptors in projection regions, could also contribute to the insensitivity of OCT2 mice to long-term venlafaxine treatment.
In conclusion, our results reveal the role of OCT2 in NE and 5-HT uptake in the brain as a complementary system to the high-affinity transporters, important for mood-related behaviors. They emphasize the importance of OCT2 in the acute action of antidepressants and indicate that this transporter is required for chronic antidepressant treatments to exert their full effects. A striking parallel can be drawn between these observations and the fact that long-term antidepressant treatments that improve symptoms in depressed patients are otherwise inactive on healthy subjects. As OCT2 appears to have a similar localization in human and rodent brain, 17 this suggests that antidepressant efficacy in man should be amenable to modulation through the manipulation of the function of this transporter. of a grant from the EGIDE foundation. Financial support was provided by the Institut National pour la Santé et la Recherche Scientifique (INSERM) and the Fondation de France.
